David A. Siegel Ventyx Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 88,400 shares of VTYX stock, worth $204,204. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,400
Previous 1,109,100
92.03%
Holding current value
$204,204
Previous $2.74 Million
82.26%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding VTYX
# of Institutions
133Shares Held
59.2MCall Options Held
180KPut Options Held
179K-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.89MShares$13.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.75MShares$8.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$8.56 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.54MShares$8.18 Million0.4% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.32 Million0.08% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $131M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...